Hepatology Communications

Article	Citations
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	116
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	111
Issue Information	107
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	104
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	79
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	68
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	67
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	65
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	63
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	63
Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis	62
Visualizing in situ viral replication across the natural history of chronic HBV infection	62
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	60
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	58
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers	55
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	51
Development and evaluation of a virtual reality driving test for patients with cirrhosis	51
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis	51
Association between widespread pain and associated symptoms in patients with cirrhosis	51
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	50
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	49
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	49
Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes	48
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	45
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	44

A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis	44
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	44
Complementary and alternative medicines and liver disease	43
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	41
Depression and anxiety management in cirrhosis	40
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	39
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	38
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)	38
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	38
Granulomatous liver diseases	37
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	36
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	36
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	35
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	35
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	35
Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?	34
High prevalence of liver fibrosis among general population: a Romanian population-based study: Erratum	34
HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression	34
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function	33
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells	33
Hepatocellular carcinoma cells downregulate NADH:Ubiquinone Oxidoreductase Subunit B3 to maintain reactive oxygen species homeostasis	33
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	33
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”	33
Increased MASH-associated liver cancer in younger demographics	32
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma	32
CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway	31
Loss of heat shock factor 1 promotes hepatic stellate cell activation and drives liver fibrosis	31
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation	31
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC	31
Fatty acid synthesis is indispensable for Kupffer cells to eliminate bacteria in ALD progression	31
Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age	30
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis	30
Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease	30
Hepatocyte TGF‐β Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let‐7b‐5p	30
Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing	30
Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis	29
Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)	28
A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis	28
Immunoglobulin M: A Neglected Serum Biomarker in Treatment‐Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase	28
Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review	28
CD36 in liver diseases	28
A need for confirmatory testing of isolated HBcAb-positive results in screening programs	27
Intestinal virome in patients with alcohol use disorder and after abstinence	27
Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy	27
Alpha-fetoprotein: Past, present, and future	26
Cellular communication networks in fibrosis: Insights from the MASLD pig model	26
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program	26
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers	26
Lipid droplet deposition in the regenerating liver: A promoter, inhibitor, or bystander?	26
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease	26

Erratum: Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children	25
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites	25
Steroid responsiveness in alcohol-associated hepatitis is linked to glucocorticoid metabolism, mitochondrial repair, and heat shock proteins	25
Clinical predictors and noninvasive imaging in Fontan-associated liver disease: A systematic review and meta-analysis	25
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021	25
iPSC-based hepatic organoids reveal a heterozygous MYO5B variant as driver of intrahepatic cholestasis	25
	25
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study	25
Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis	24
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways thro	24
Falls and malnutrition are associated with in-hospital mortality in patients with cirrhosis	24
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis	24
Meaningful differences in patient-reported outcome measurement scores in liver disease	24
Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS	24
Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients	23
A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance	23
The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study	23
A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis	23
Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis	23
Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans	23
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment	23
CD4+ T-cell subsets in autoimmune hepatitis: A review	23
Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives	22
Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning	22
	22
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial	22
Diet composition impacts the natural history of steatotic liver disease	22
Erratum: Use and outcome of transjugular intrahepatic portosystemic shunt in hospitalized patients Germany:Nationwide study (2007-2018)	22
Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies	22
Erratum: Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality	22
A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): An alternative of Baveno VI criteria: Erratum	22
Reply: Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping?	21
Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease	21
Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction	21
Reply: Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?	21
Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways	21
Low awareness of MASLD among U.S. adults: Trends from NHANES 2017–2023	21
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening	21
Functional involvement of endothelial lipase in hepatitis B virus infection	21
Growth hormone deficiency and NAFLD: An overlooked and underrecognized link	21
Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice	21
Response to Tinospora cordifolia (Giloy)‐induced liver injury during the COVID‐19 pandemic—Multicenter nationwide study from India	20
Aspirin is associated with a reduced incidence of liver disease in men	20
A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction–associated steatotic liver disease	20
Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs	20
Reproducibility of vibration-controlled transient elastography, controlled attenuation parameter, and blood tests in cirrhosis	20
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid	20
An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD	19
	19
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease	19
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria	19
	19
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis	19
Acute on chronic liver failure: prognostic models and artificial intelligence applications	19
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment	19
Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2−/− mouse model of sclerosing cholangitis via immunomodulatory effects	19
NME2 modulates HCC progression through 4EBP1 phosphorylation and autophagy regulation independent of mTOR	18
Erratum: BTLA deficiency promotes HSC activation and protects against hepatic ischemia-reperfusion injury	18
Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum	18
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis	18
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3	18
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis	18
Erratum: Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD)	18
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target	17
Severe Alcohol‐Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure	17
METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis	17
Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review	17
Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling	17
A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis	17
Gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage	17
Hepatocyte dedifferentiation in 2D culture reveals extensive transcriptomic and proteomic rewiring	17
miR-34a regulates macrophage-associated inflammation and angiogenesis in alcohol-induced liver injury	17
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors	16
Post-translational modifications drive the effects of HMGB1 in alcohol-associated liver disease	16
Severe acute hepatitis of unknown etiology in a large cohort of children	16
Population screening for cirrhosis	16
Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model	16
The burden of extrahepatic organ failures in European patients with cirrhosis	16
EGFR activation in cholangiocytes promotes extrahepatic bile duct regeneration after injury	16
Clinical utility of two-step hepatitis E virus IgM antibody testing in a low-prevalence setting: A 10-year retrospective multicenter study	16

Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease	16
Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7‐year national inpatient sample study	16
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial	16
Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases	16
Interleukin-18 binding protein protects against metabolic steatohepatitis	16
The most impactful findings on liver cancer in 2023	16
Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling	16
Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis	15
Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death	15
Deficiency of Ugcg in LSECs alleviates high-fat diet-induced MASLD	15
Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC	15
Activin B promotes the initiation and progression of liver fibrosis	15
Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease	15
ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway	15
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature	15
Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study	15
NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation	15
The impact of aging on liver health and the development of liver diseases	15
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models	15
Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy	15
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018	15
Neighborhood disparities and metabolic dysfunction–associated steatotic liver disease in children with overweight or obesity	15
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index	14
Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study	14
Long-term HBV infection of engineered cultures of induced pluripotent stem cell-derived hepatocytes	14
	14
Neurogastroenterology and motility disorders in patients with cirrhosis	14
Immune‐mediated liver injury following COVID‐19 vaccination: A systematic review	14
Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV	14
Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice	14
A versatile method to profile hepatitis B virus DNA integration	14
Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis	14
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus	14
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores	14
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening	14
	14
An optimized peritonitis-induced ACLF model that reproduces the full spectrum of extrahepatic organ failures in mice	14
Ablation of high‐mobility group box‐1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling‐deficient mice	13
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study	13
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis	13
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD	13
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis	13
Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study	13
HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B	13
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis	13
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population	13
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	13
Portal cavernoma cholangiopathy: A systematic review of current understanding, clinical significance, and management	13
Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival	13
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	13
The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study	13
Heterologous adenovirus‐vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients	13
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	13
The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD	13
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	13
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy	13
Direct Conversion of Human Endothelial Cells Into Liver Cancer‐Forming Cells Using Nonintegrative Episomal Vectors	13
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents	13
Long-term outcomes after ICU admission in critically ill patients with liver cirrhosis: An Australian state-wide cohort study	13
Erratum: Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	13
Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes	13
Assessing the risk of surgery in patients with cirrhosis	13
Erratum: Live-smart: A sequential, multiple assignment randomized trial to reduce falls in cirrhosis	12
Financial burden in a US cohort of patients with HCC	12
Cytomegalovirus infection in patients with biliary atresia—further questions and possible solutions	12
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice	12
Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis	12
Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis	12
Issue Information	12
Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study	12
HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma	12
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study	12
Role of mitogens in normal and pathological liver regeneration	12
Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3‐mediated cancer development	12
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study	12
Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis	12
Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list	12
Ethanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking	12
Reply	12
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores	12
Baveno VII for HCC: Are we there yet?	12
Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity	12
LKB1 acts as a critical brake for the glucagon‐mediated fasting response	12
Maternal Western diet is associated with distinct preclinical pediatric NAFLD phenotypes in juvenile nonhuman primate offspring	12
Cellular communication network factor 1‐stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis	12
Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease	12
Missense variants in the TRPM7 α-kinase domain are associated with recurrent pediatric acute liver failure	11
Year in review: Liver cancer research in 2022: tumor microenvironment takes the central stage: Erratum	11
BTLA deficiency promotes HSC activation and protects against hepatic ischemia-reperfusion injury	11
Reply: Critical commentary on the study comparing TIPS, tunneled peritoneal catheter, and ascites pump in refractory ascites	11
Erratum: Regulation of immune responses in primary biliary cholangitis: A transcriptomic analysis of peripheral immune cells	11
ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies	11
Reply—Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research	11
Serum Mac‐2 binding protein level predicts the development of liver‐related events and colorectal cancer in patients with NAFLD	11
Health economic outcomes of a minimal monitoring approach to providing HCV therapy	11